Literature DB >> 12642739

Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection.

G K Anagnostopoulos1, P Kostopoulos, G Margantinis, S Tsiakos, D Arvanitidis.   

Abstract

GOALS: To establish whether omeprazole plus azithromycin in association with either amoxicillin or tinidazole is effective in curing Helicobacter pylori infection in dyspeptic patients.
BACKGROUND: Many antibiotics in combination with antisecretory drugs have been used in an attempt to find the optimal regimen for eradication of H. pylori. Azithromycin is a macrolide that achieves high concentrations in gastric tissue after a single 500-mg oral dose. STUDY: A total of 160 consecutive symptomatic patients with H. pylori received omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, and were randomly assigned to either amoxicillin 1 g twice daily (OAzAm group, n = 80) for 1 week or tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80). H. pylori status was assessed by rapid urease test and histology at entry and by histology and (13)C-urea breath test after the end of the therapy.
RESULTS: H. pylori was eradicated in 62.5% of patients in the OAzAm group (intention to treat [ITT] 62.5%) and in 71.2% of patients in the OAzT group (ITT 71.2%).
CONCLUSIONS: Although the compliance was excellent and the side effects negligible, the regimens used were partially effective for the eradication of H. pylori.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642739     DOI: 10.1097/00004836-200304000-00009

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

Authors:  Shahrokh Mousavi; Jafar Toussy; Siamak Yaghmaie; Mehrdad Zahmatkesh
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis.

Authors:  Jie Dong; Xiao-Feng Yu; Jian Zou
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

3.  Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA.

Authors:  Can Xu; Zhao-Shen Li; Yi-Qi Du; Zhen-Xing Tu; Yan-Fang Gong; Jing Jin; Hong-Yu Wu; Guo-Ming Xu
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

4.  Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2.

Authors:  Can Xu; Zhao-Shen Li; Yi-Qi Du; Yan-Fang Gong; Hua Yang; Bo Sun; Jing Jin
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.